Close
Sukeshi Patel Arora, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Sukeshi Patel Arora, MD
Sukeshi Patel Arora, MD, is an associate professor in the Division of Hematology and Medical Oncology at The University of Texas Health Science Center San Antonio and is the leader of the gastrointestinal malignancies and geriatric oncology program at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. She received her medical degree from the University of Texas Southwestern Medical School in Dallas, Texas. She completed her internal medicine residency and hematology-oncology fellowship at UT Health San Antonio.
She specializes in medical oncology treatments for gastrointestinal cancers, including gallbladder, bile duct, pancreas, liver and neuroendocrine cancers. Her research interests are drug development for new treatments for hepatobiliary and pancreatic cancers and improving the care for older adults with cancers. She is also a faculty member in Mays Cancer Center's cancer genetics and high-risk screening clinic.
Gender
- Female
Languages Spoken
- English
- Spanish
- Hindi
- Gujarati
-
Credentials
Credentials
Positions
- Associate Professor, University of Texas Health Science Center San Antonio
- Leader, Gastrointestinal Malignancies Program, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- American Board of Internal Medicine, Hematology
Education
- Medical School: University of Texas Southwestern Medical School, Dallas, Texas
- Residency: Internal Medicine, University of Texas Health Science Center San Antonio, San Antonio, Texas
- Fellowship: Hematology/Oncology, University of Texas Health Science Center San Antonio, San Antonio, Texas
-
Locations & Contact
Locations & Contact
She is very compassionate and really listened to my concerns.
Patient
-
Research & Publications
Research & Publications
View all research & publications - Sukeshi Arora, M.D.
-
Clinical Trials
Clinical Trials
Type of Cancer
Colon
ClinicalTrials.gov Identifier
NCT02891538
Principal Investigator
Sukeshi Patel Arora MD
A Pilot Study to Evaluate the Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal cancer (CRC) Patients with Curative Resections.
This will be a randomized, controlled pilot trial of patients with histological documentation of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer. If patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, then the patient is eligible. All eligible subjects will be consented prior to surgery.
Type of Cancer
Liver
ClinicalTrials.gov Identifier
NCT03037437
Principal Investigator
Sukeshi Patel Arora MD
Modulation of Sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer (CTMS# 16-0076)
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
ClinicalTrials.gov Identifier
NCT01150045
Principal Investigator
Sukeshi Patel Arora MD
CALGB-80702: A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant FOLFOX Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer (CTMS# 14-2011)
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways…
ClinicalTrials.gov Identifier
NCT01349881
Principal Investigator
Sukeshi Patel Arora MD
S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colo
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Type of Cancer
Liver
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora MD
Characterizing disease biology, treatment patterns and toxicity in older adults with advanced hepatocellular carcinoma (CTMS# 19-0010)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora MD
S1815, A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (CTMS# 19-0084)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora MD
Phase I study of TTI-101, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with advanced cancers. CTMS#: 21-0019
Type of Cancer
Metastases, Colorectal Cancer
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora MD
daNIS-3: An Open-Label, Multi-Center, Phase II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With Standard of Care (SOC) Anti-Cancer Therapy for the Second Line Treatment of Metastatic Colorect
This study evaluates the preliminary efficacy and safety of NIS793 and other novel investigational combinations with SOC anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of metastatic colorectal cancer.
Type of Cancer
Liver and Hepatobilary Cancer
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora MD
Protocol 10476: A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers (CTMS# 22-0023)
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery (unresectable).
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sukeshi Patel Arora MD
Biomarker development for predicting immune checkpoint therapy efficacy of hepatocellular carcinoma (CTMS# 22-0050)
We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study.